Meike H. van der Ree

Micrornas: Role and Therapeutic Targets in Viral Hepatitis

N. Kootstra, P. Jansen, H. Reesink, 2014, Antiviral therapy.

Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial

A. Pavlícek, N. Kootstra, M. van der Valk, 2017, The Lancet.

Immune responses in DAA treated chronic hepatitis C patients with and without prior RG-101 dosing

P. Klenerman, Leo Swadling, E. Barnes, 2017, Antiviral research.

Long-term safety and efficacy of microRNA-targeted therapy in chronic hepatitis C patients.

S. Zeuzem, H. Janssen, V. Kupčová, 2014, Antiviral research.

Deep sequencing identifies hepatitis B virus core protein signatures in chronic hepatitis B patients

K. Feenstra, N. Kootstra, H. Reesink, 2018, Antiviral research.

Immune phenotype and function of natural killer and T cells in chronic hepatitis C patients who received a single dose of anti‐MicroRNA‐122, RG‐101

P. Klenerman, Leo Swadling, E. Barnes, 2017, Hepatology.

Plasma MicroRNA Levels Are Associated With Hepatitis B e Antigen Status and Treatment Response in Chronic Hepatitis B Patients

N. Kootstra, R. Takkenberg, H. Reesink, 2017, The Journal of infectious diseases.